Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.

ABSTRACT: This Review discusses the various types of non-coding oligonucleotides, which have garnered extensive interest as new alternatives for targeted cancer therapies over small molecule inhibitors and monoclonal antibodies. These oligonucleotides can target any hallmark of cancer, no longer limited to so-called "druggable" targets. Thus, any identified gene that plays a key role in cancer progression or drug resistance can be exploited with oligonucleotides. Among them, small-interfering RNAs (siRNAs) are frequently utilized for gene silencing due to the robust and well established mechanism of RNA interference. Despite promising advantages, clinical translation of siRNAs is hindered by the lack of effective delivery platforms. This Review provides general criteria and consideration of nanopart

SUBMITTER: Ngamcherdtrakul W 

PROVIDER: S-EPMC4826844 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature